By: IPP Bureau
Last updated : May 26, 2025 11:35 am
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Gland Pharma Ltd posted 3.1 per cent YoY drop in net profit for the quarter ended March 31, 2025 at Rs. 186.5 crore as against Rs. 192.4 crore in the year-ago quarter of FY24. Revenue from operations fell 7.3 per cent YoY to Rs. 1,424.9 crore from Rs. 1,537.5 crore in Q4 FY24.
Its EBITDA in the quarter fell 3.1 per cent to Rs. 347.5 crore from Rs. 358.6 crore a year ago. However, EBITDA margin came in at 24.4 per cent from 23.3 per cent in the year-ago period.
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4 revenue. For the year, R&D investments were Rs. 192.2 crore or 4.7 per cent of revenue, consistent with the company’s continued emphasis on product development.
During Q4, Gland Pharma introduced four new molecules latanoprost, midazolam bags RTU, dexamethasone and new strengths of vancomycin. That took the total number of product launches in FY25 to 31.
During Q4 FY25, the company filed five ANDAs and received seven approvals. For the complete 12 months, Gland filed 24 ANDAs and obtained 32 approvals. To the end of March 2025, the company had filed 371 ANDAs in the US, with 318 approved and 53 pending.